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Vector-mediated delivery of short-hairpin RNA (shRNA) to regulate gene expression holds a great
therapeutic promise. We hypothesize that gene expression can be autoregulated with RNA interfer-
ence. We used inducible nitric oxide synthase (iNOS) as a gene model to test this hypothesis. Lipo-
polysaccharide dose-dependently increased iNOS in rat aortic smooth muscle cells and the nitrite
production from these cells. These increases were attenuated in cells transfected with plasmids con-
taining code for iNOS shRNA whose expression was controlled by an iNOS promoter. The production
of shRNA was lipopolysaccharide dose-dependent. The lipopolysaccharide-induced iNOS expression
in rat C6 glioma cells also was attenuated by transfection with plasmids containing the iNOS shRNA
code. These results provide proof-of-concept evidence for using RNA interference technique to
achieve autoregulation of gene expression.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RNA interference (RNAi) caused by endogenous microRNA is a
naturally occurring molecular machinery to regulate protein
expression [1]. To simulate this mechanism, small interfering
RNA (siRNA) or short hairpin RNA (shRNA) can be introduced into
cells to silence the expression of a selective protein. Direct delivery
of siRNA to cells may have a limited application under in vivo con-
ditions because of the difﬁculty for the siRNA to access target cells
and the short life of these molecules. Vector-mediated delivery of
shRNA holds great therapeutic potentials under in vivo conditions.
Once the vector is delivered to cells, shRNA can be synthesized in
these cells. One of popular methods for this purpose is to construct
the vector in a way that the expression of shRNA is controlled by a
polymerase (pol) III promoter [2]. Pol III promoters are usually
short and well-deﬁned, making them easy to be cloned into vectors
and to be used to facilitate accurate transcription of shRNA.
Use of pol III promoters to control shRNA expression can have
signiﬁcant problems. Pol III promoters are constitutively active in
many cell types. This feature makes them not suitable to provide
spatial and temporal control of shRNA expression [3]. In addition,
pol III promoters are usually very efﬁcient. Robust expression of
shRNA can saturate the endogenous microRNA processing machin-
ery, which appears to induce cell toxicity in some cases [4]. Tochemical Societies. Published by E
nesthesiology, University of
800710, Charlottesville, VAovercome these problems, various methods, such as introduction
of an inducible element to the promoters and use of tissue speciﬁc
pol II promoters, have been reported [5–7]. Although better spatial
and temporal control can be achieved by these modiﬁcations, the
expression of shRNA will be at its maximal level once the control
mechanisms for the expression are activated.
Fine regulation of protein/gene expression may be desirable in
most situations. For example, The damaging role of over-expres-
sion of inducible nitric oxide synthase (iNOS) after brain ischemia
has been well established [8–10]. However, iNOS has many physi-
ological functions, such as antitumoral and immunomodulatory
effects [11,12] and is involved in neurogenesis after brain ischemia
[13]. Thus, ﬁne regulation of iNOS expression after brain ischemia
may be necessary to reduce ischemic brain injury and to preserve
neurogenesis. Such a ﬁne regulation may be achieved via an auto-
regulation mechanism using RNAi technique. To provide proof-of-
concept evidence, we constructed a vector in which the expression
of iNOS shRNA was under the control of an iNOS promoter. This
construction was designed to induce iNOS shRNA expression by
the endogenous factors that could induce iNOS expression, allow-
ing autoregulation of iNOS expression.
2. Materials and methods
2.1. DNA constructs
The backbone plasmid pcDNA6.2-GW/EmGFP-miR was from
Block-iT PolII miR RNAi expression vector kit (Invitrogen, Carlsbad,
CA). The plasmids pcDNA6.2-GW/EmGFP-miR-iNOS (pCMV-shRNA)lsevier B.V. All rights reserved.
Fig. 1. Effectiveness of the silencing effects of iNOS shRNAs and the induction of
iNOS shRNA production. (A) A diagram showing the basic structure of the plasmids
used in the study. (B) Human 293FT cells were co-transfected with the plasmid
pCMV-iNOS and various pCMV-shRNA plasmids indicated in the ﬁgure. RNA was
prepared at 24 h after the transfection. Results are means ± S.D. (n = 3). ^P < 0.05
compared with pCMV-N group. (C) RASMCs were transfected with various plasmids
indicated in the ﬁgure. Twenty four hours later, they were incubated with various
concentrations of lipopolysaccharide for 12 h and then harvested for shRNA4
quantiﬁcation. Results are means ± S.D. (n = 3). ⁄P < 0.05 compared with piNOS-
shRNA4 at 0 lg/ml lipopolysaccharide.
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pcDNA6.2-GW/EmGFP-miR-neg (pCMV-N) containing an unrelated
insert were constructed using amethod described in themanual for
theBlock-iT PolIImiRRNAi expression vector kit. Six iNOS shRNAse-
quences were designed with the use of the website http://
www.invitrogen.com/rnai and were shown as in Table 1. The unre-
lated insert sequence was predicted not to target any known genes.
To replace the CMV promoter with the rat iNOS promoter in the
above plasmids, we ﬁrst cloned the iNOS promoter from rat C6 gli-
oma cells (American Type Culture Collection, Manassas, VA) by PCR
ampliﬁcation using the forward primer 50-AAAGTATTTGGGA
GGAGGGGCTGAG-30 and the reverse primer 50-AGAGCTCACTCCCT
GTAAAGCTGTGG-30. This process introduced a Sac I site. The PCR
product was blunted and then digested with Sac I. This process
resulted in a 3.2 kb iNOS promoter that was found to have a full re-
sponse to the regulation of various transcription factors for iNOS
expression [14]. The plasmids containing CMV promoters were di-
gested with Spe I ﬁrst, blunted and digested with Sac I. The iNOS
promoter then was sub-cloned into each plasmid to generate var-
ious piNOS-shRNAs and piNOS-N (Fig. 1).
To construct the plasmid containing the code for rat iNOS, total
RNA was extracted from rat aortic smooth muscle cells (RASMCs,
Lonza, Walkersville, MD) simulated by lipopolysaccharide (LPS),
an inducer of iNOS expression, and was reversely transcribed into
cDNA. The cDNA then was ampliﬁed with the iNOS forward primer
50-CCACCTTGGTGAGGGGACTGGA-30 and the reverse primer 50-
AGGGCCAGATGCTGTAACTCTTCT-30. The PCR product was cloned
into the pTARGET vector (Promega, Madison, WI) to form pCMV-
iNOS.
All plasmids were sequenced to conﬁrm accuracy of their se-
quences and puriﬁed by using Qiagen Hispeed Plasmid Puriﬁcation
kit (Qiagen, Valencia, CA).
2.2. Cell culture and transfection
RASMCs were maintained in Dulbecco’s Modiﬁed Eagle’s Med-
ium (DMEM)/F12 medium supplemented with 20% heat inacti-
vated fetal bovine serum (FBS) at 37 C. Human 293FT cells were
from Invitrogen and maintained in DMEM supplemented with
10% FBS, 0.1 mM MEM non-essential amino acids, 6 mM L-gluta-
mine, 1 mM MEM sodium pyruvate and 500 lg/ml Geneticin. Rat
C6 glioma cells were maintained in F-12 K medium supplemented
with 15% horse serum and 2.5% FBS at 37 C.
To determine the effectiveness of selected iNOS shRNAs in
silencing the expression of rat iNOS, 1  105 293FT cells per well
were plated in 12-well plates. Next day, the cells were transfected
with 720 ng pCMV-iNOS and 240 ng pCMV-shRNA or pCMV-N
using 1.5 ll FuGENE HD Transfection Reagent (Promega). RNA iso-
lation from these cells was performed at 24 h after transfection.
To determine whether the production of iNOS shRNA and its
silencing effect were LPS dose-dependent, 1  105 RASMCs per
well were plated in 6-well plates. Cells were transfected with
2 lg piNOS-shRNA3, piNOS-shRNA4 or piNOS-N using 8 ll FuGENE
HD Transfection Reagent. Since CMV promoter is much smaller
than iNOS promoter, pCMV-shRNA was mixed with pCMV-N so
that the same moles of pCMV-shRNA as contained in 2 lg piNOS-Table 1







Unrelated insert 50-TGCTGGAAATGTACTGCGCGTGshRNA plasmids were used in the transfection. Twenty four hours
after transfection, cells were washed, incubated in fresh medium
with different concentrations of LPS for 12 h and then used for
RNA preparation.
C6 cells were plated at 4  105 cells per well in 6-well plates.
They were transfected with 2 lg plasmids per well using the
GenJet transfection reagents (SignaGen laboratories, Rockville,MD).
2.3. Cell sorting
Twenty hours after transfection, C6 cells were trypsinized and







Fig. 2. Does-response of lipopolysaccharide to induce iNOS expression and nitrite
production. (A) RASMCs were transfected with various plasmids indicated in the
ﬁgure. Twenty four hours later, they were incubated with various concentrations of
lipopolysaccharide for 12 h and then harvested for iNOS mRNA quantiﬁcation.
Results were normalized by the level of iNOS mRNA in cells transfected with piNOS-
N at 0 lg/ml lipopolysaccharide. Reduction of iNOS mRNA abundance in cells
transfected with piNOS-shRNA3 or piNOS-shRNA4 was calculated by subtracting
mRNA levels in the cells transfected with piNOS-N from the mRNA levels in the cells
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Reﬂection Cell Sorter (iCyt, Champaign, IL). Cells with GFP were
collected and immediately plated onto 12-well plates at a density
of 3  105 per well. Cells were cultured overnight, and LPS was
added into the wells to make the ﬁnal concentration of 1 lg/ml.
Three hours later, cells were collected for RNA isolation.
2.4. Total RNA extraction and real-time PCR
Total RNA was extracted using RNeasy micro kit (Qiagen). Real-
time PCR was performed as we described previously [15]. Primers
for real-time PCR were designed based on reported sequence of rat
iNOS gene using the Primer Express 3.0 software (Applied Biosys-
tems, Carlsbad, CA) and selected to best ﬁt the requirement of SYBR
Green assays. The sequences of the primers are: forward, CAC-
TGGGACTGCACAGAATGTT and reverse, CTCCATTGCCCCAGTTTTTG.
These primers are not suitable to amplify human iNOS cDNA due to
the sequence difference between the rat and human iNOS. Quanti-
tative PCRs were carried out in triplicates using each cDNA sample
that was equivalent to 50 ng of starting total RNA. Power SYBR
Green Master Mix was used with the forward and reverse primers
at the optimized concentrations in a total volume of 25 ll. Ampli-
fying PCR and monitoring of the ﬂuorescent emission in real-time
were performed in the ABI Prism 7900HT Sequence Detection Sys-
tem (Applied Biosystems). To verify that only a single PCR product
was ampliﬁed per transcript, dissociation curve data was analyzed
through the 7900HT Sequence Detection Software. To account for
possible differences in starting material, PCR of the housekeeping
genes glyceraldehydes-3-phosphate dehydrogenase and actin also
was carried out for each cDNA sample. The relative amount of iNOS
mRNA in each sample was determined using the comparative
threshold cycle method and then normalized to those of house
keeping genes.
2.5. MicroRNA isolation and assay
MicroRNA was isolated using mirVana miRNA isolation kit
(Ambion, Carlsbad, CA) and quantiﬁed by TaqMan microRNA assay
kit (Applied Biosystems). Quantitative PCR was carried out in trip-
licates using U6 snRNA as control. Amplifying PCR and Monitoring
of the ﬂuorescent emission in real time were performed in the ABI
Prism 7900HT Sequence Detection System.
2.6. Nitrite assay
Twenty-four hours after transfection, freshmediumwith various
concentrations of LPS was added to the cells. The culture medium
was collected after a 24-h incubation. The nitrite concentrations
were measured using the Griess Reagent kit (Invitrogen) as we de-
scribed previously [16].
2.7. Data analysis
The results are presented as means ± S.D. (nP 3). Statistical
analysis was performed by one way analysis of variance followed
by the Tukey test after conﬁrmation of normal distribution of the
data or by Kruskal–Wallis analysis of variance on ranks followed
by the Tukey test when the data are not normally distributed. A
P < 0.05 was considered signiﬁcant.transfected with those plasmids containing iNOS shRNA codes. Results are
means ± S.D. (n = 3). ⁄P < 0.05 compared with piNOS-N at 0 lg/ml lipopolysaccha-
ride. (B) The culture medium from the cells used in panel A was collected for nitrite
measurement. Reduction of nitrite concentrations in cells transfected with piNOS-
shRNA3 or piNOS-shRNA4 was calculated by subtracting nitrite concentrations of
the cells transfected with piNOS-N from the concentration of the cells transfected
with those plasmids containing iNOS shRNA codes. Results are means ± S.D. (n = 6).
⁄P < 0.05 compared with piNOS-N at 0 lg/ml lipopolysaccharide.3. Results
The human 293FT cells, a cell line with a very high transfection
rate, were co-transfected with the plasmids pCMV-shRNA and
pCMV-iNOS to evaluate the effectiveness of the selected shRNAsto silence rat iNOS expression. This co-transfection system avoids
interference of endogenous iNOS expression. As shown in Fig. 1,
all six shRNAs signiﬁcantly inhibited the rat iNOS expression.
Since the 3.2 kb iNOS promoter was found to be fully functional
in RASMCs [14], we used these cells for the majority of our study.
LPS induced a dose-dependent increase of shRNA4 in the RASMCs
transfected with piNOS-shRNA4. A high level of shRNA4 was found
in the RASMCs transfected with pCMV-shRNA4. However, the
shRNA4 expression in these cells was not affected by LPS. Cells
transfected with piNOS-N did not express reliably detectable
shRNA4 by our method, nomatter whether LPS was present (Fig. 1).
LPS caused a dose-dependent increase of iNOS mRNA in the
RASMCs transfected with piNOS-N. This increase was attenuated
in the RASMCs transfected with piNOS-shRNA3 or piNOS-shRNA4.
The degree of this attenuation was LPS dose-dependent (Fig. 2).
Similar change pattern was observed in the nitrite concentrations
in the culture medium of the RASMCs (Fig. 2).
To determine whether the ﬁndings in the RASMCs were applica-
ble to another type of cells, C6 cells were used. C6 cells transfected
Fig. 3. Silencing effects of iNOS shRNAs in C6 cells. (A, B) Rat C6 cells were
transfected with the plasmid piNOS-N that contained a code for green ﬂuorescent
protein. Photos were taken 24 h later. Panel A is a phase contrast picture to show all
cells. Panel B is a ﬂuorescent image to show cells transfected by the vector. (C) C6
cells were transfected with or without plasmids indicated in the ﬁgure and were
sorted based on their expression of green ﬂuorescent protein. Cells that were
transfected successfully by the corresponding plasmids were exposed to 1 lg/ml
lipopolysaccharide for 3 h before they were harvested for real-time PCR for
quantiﬁcation of iNOS and actin mRNA. The iNOS results were normalized by actin
data from the same sample. Results are means ± S.D. (n = 6). ⁄P < 0.05 compared
with iNOS-N group.
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the code for GFP was downstream of iNOS promoter in this plas-
mid, these results suggest that the iNOS promoter was activated
in these cells. Since these cells had a much lower transfection rate
(25%) than human 293FT cells and RASMCs, we separated cells
that were transfected successfully with piNOS-shRNA1, piNOS-
shRNA2, pCMV-N or piNOS-N from those that were not by ﬂow
cytometry. Cells transfected with piNOS-shRNA1 or piNOS-shRNA2
expressed signiﬁcantly less iNOS mRNA than cells transfected with
piNOS-N after LPS stimulation (Fig. 3).
4. Discussion
We used iNOS as an example for a group of genes whose over-
expression is harmful to cells. However, normal expression of these
genes is necessary for various physiological functions. Thus, ﬁne
regulation of the expression of these genes is critical, especially
in disease status. For example, robust iNOS expression is induced
in microglia, astrocytes and neurons of ischemic brain [17–19].
Studies with iNOS inhibitors and iNOS knockout mice conﬁrm that
a decreased iNOS activity can reduce ischemic brain injury [9,20–
26]. However, iNOS has been shown to participate in induction of
ischemic tolerance [27,28] and neurogenesis after brain ischemia
[13]. Thus, prevention of iNOS over-expression may block its dam-
aging effects and preserve its beneﬁcial effects after brain ische-
mia. To achieve this goal, we proposed to use an autoregulation
mechanism in which the iNOS shRNA expression was controlled
by an iNOS promoter. Thus, stimuli that induce iNOS expression
also will cause the iNOS shRNA expression. Stronger stimuli for
iNOS expression will induce a higher expression of iNOS shRNA,
which then attenuates iNOS increase.To test our theory, we ﬁrst identiﬁed shRNAs that were effective
in silencing rat iNOS expression. Among them, shRNA4 appeared to
be the most effective. When the RASMCs were transfected with pi-
NOS-shRNA4, LPS dose-dependently increased shRNA4 in these
cells. The shRNA4 expression in the RASMCs transfected with
pCMV-shRNA4 was not affected by LPS. These results suggest that
our iNOS promoter is functional and that the expression of shRNA4
under the control of this promoter is inducible. These results, along
with the results that a bigger decrease of iNOS mRNA abundance
was seen when cells transfected with piNOS-shRNAs were stimu-
lated by a higher LPS concentration, provide strong proof of con-
cept evidence for using our technique to achieve autoregulation
of gene expression. This gene autoregulation may have signiﬁ-
cantly affected the iNOS activity because the nitrite contents in
the culture medium had a change pattern similar to that of iNOS
mRNA expression. iNOS, once it is formed, produces nitric oxide,
a short lived signaling molecule [29]. Nitrite is a stable oxidative
product of nitric oxide and is often used to reﬂect nitric oxide lev-
els [16].
In addition to the RASMCs, our piNOS-shRNAs were also effec-
tive to attenuate the LPS-stimulated iNOS expression in C6 cells.
These results suggest that induction of autoregulation of iNOS
expression is not cell type speciﬁc.
The novel concept, autoregulation of gene expression by RNAi,
could have a broad application. For example, autoregulation of
iNOS expression by RNAi may be used in brain ischemia to provide
neuroprotection because iNOS contributes to ischemic brain injury
[8–10]. The technique also can be used to autoregulate expression
of other proteins, such as cytokines, and, thus, hinder many disease
processes including inﬂammation in which iNOS and cytokines
play an important role [30,31]. Use of suitable viral delivery system
will facilitate the possible application of this technique under
in vivo conditions.
Various modiﬁcations of our approach to achieve autoregula-
tion of gene expression by RNAi can be performed. For example,
it is possible to enhance or decrease shRNA expression by including
or excluding certain regulatory elements in the promoter used to
control shRNA expression. These ﬁne tunes are necessary to
achieve the intended goals under various laboratory and clinical
conditions.
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